Opus Genetics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Opus Genetics Inc 's ROA in the second quarter of 2026?
Opus Genetics Inc recorded a cumulative net loss of $-115 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -186.9%.

However, within the Healthcare sector 845 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4511, from total ROA ranking in the first quarter of 2026 at 5002.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	140.44 %	38.66 %	36.3 %	-7.05 %	-13.76 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-115	-107	-50	-33	-23
Return On Assets (TTM)	-186.9 %	-222.99 %	-114.53 %	-82.77 %	-56.94 %
IRD's Total Ranking	# 4511	# 5002	#	#	#
Total Assets (TTM) in million	93	67	50	36	39
Seq. Total Assets Change	39.2 %	32.93 %	39.09 %	-6.58 %	-19.73 %
Seq. Net Income Change	-	-	-	-	-

IRD's 5 Years Annual ROA >> Back to IRD Management Effectiveness >> Compare IRD ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 400
Sector	# 846
Overall	# 4423

Return On Assets Statistics
High	Average	Low
70.19 %	-90.72 %	-508.4 %
(Dec 31 2022)		(Mar 31 2021)

Financial Statements
Opus Genetics Inc 's Assets	$ 93 million	IRD's Balance sheet
Opus Genetics Inc 's Income	$ -15 million	Quarterly IRD's Income Statement
IRD's Income by Division		See IRD's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	36.3 %	-29.84 %	7.24 %	87.87 %	47.48 %
Total Assets in million	50	37	53	49	26
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-50	-58	-10	18	-57
Annual Return On Assets	-98.7 %	-156.07 %	-19.01 %	36.51 %	-217.41 %

IRD's 5 Years Annual ROA >> Back to IRD Management Effectiveness >> Compare IRD ROA to its Competitors

More Return On Assets Ratios
IRD's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
IRD's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for IRD's Competitors
Subscribers only: Roa for Opus Genetics Inc 's Suppliers
Subscribers only: Return On Assets for IRD's Customers

You may also want to know
IRD's Roi	IRD's Inventory Turnover Ratio	IRD's Growth Rates	IRD's Dividend Comparisons
	IRD's Profitability Ratios	IRD's Asset Turnover Ratio	IRD's Dividend Growth
IRD's Roe	IRD's Valuation Ratios	IRD's Financial Strength Ratios	IRD's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-05T15:15:09+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.